)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Immuneering (IMRX) investor relations material
Immuneering Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary13 Aug, 2025
Executive summary
Atebimetinib advanced in Phase 2a trials, showing 94% OS and 72% PFS at six months in first-line pancreatic cancer; median OS and PFS not reached.
Regulatory feedback on pivotal trial plans expected in Q4 2025, with trial initiation planned for 2026.
Strategic focus shifted to atebimetinib after pausing IMM-6-415; partnership opportunities for IMM-6-415 are being explored.
U.S. composition of matter patent granted for atebimetinib, providing exclusivity into 2042 and potential extension to 2044.
Net loss for the six months ended June 30, 2025 was $29.5 million, with an accumulated deficit of $253.8 million and $26.4 million in cash and cash equivalents.
Financial highlights
Net loss was $14.4 million for Q2 2025, up 2.5% year-over-year; net loss for the six months ended June 30, 2025 was $29.5 million, up 3.9% year-over-year.
R&D expenses for Q2 2025 were $10.5 million, slightly down from $10.7 million in Q2 2024; for the six months, R&D expenses were $21.9 million, up 0.3% year-over-year.
G&A expenses for Q2 2025 were $4.3 million, unchanged from Q2 2024; for the six months, G&A expenses were $8.3 million, down 0.8% year-over-year.
Cash used in operating activities was $23.5 million for the six months ended June 30, 2025; net cash provided by financing activities was $13.7 million, mainly from ATM equity sales.
Cash and cash equivalents were $26.4 million as of June 30, 2025, down from $36.1 million at December 31, 2024.
Outlook and guidance
Existing cash and cash equivalents expected to fund operations into 2026; additional capital will be required to continue beyond that point.
Updated OS and PFS data from the Phase 2a atebimetinib trial expected in Q3 2025.
Plans to initiate a registrational trial for atebimetinib in combination with mGnP in 2026, pending regulatory feedback.
If unable to raise additional capital, significant reductions in spending or operational scale-back may be necessary.
When will Immuneering share updated OS/PFS data?
Discuss the atebimetinib patent's potential impact.
Explain the R&D expense decrease in Q2 2025.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Immuneering earnings date
Q3 202510 Nov, 2025
Next Immuneering earnings date
Q3 202510 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Immuneering Corporation is a clinical-stage oncology company focused on developing novel therapeutics for cancer patients. The company leverages bioinformatics and computational biology to design drugs that cyclically disrupt core oncogenic signaling pathways, such as the MAPK pathway, with the aim of reducing tumor growth while minimizing toxicity. Immuneering’s pipeline includes its lead product candidate, IMM-1-104, a dual-MEK inhibitor in clinical trials targeting cancers caused by mutations in RAS and/or RAF. Another notable candidate is IMM-6-415, also targeting solid tumors. The company emphasizes a disease-agnostic approach, aiming to address cancers with high unmet medical needs through insights derived from its translational bioinformatics platform. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage